Branded Generic Market Research Report By Dosage Form (Oral, Injectable, Transdermal, Topical, Inhalable), By Therapeutic Area (Cardiovascular, Oncology, Central Nervous System, Metabolic Disorders, Anti-infective), By Generic Equivalent (Biosimilar, Non-Biosimilar), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Wholesale Distributors), By Product (branded products, generic products) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Forecast to 2032

Branded Generic Market Overview

Branded Generic Market Size was estimated at 21.21 (USD Billion) in 2022. The Branded Generic Market Industry is expected to grow from 22.21 (USD Billion) in 2023 to 33.5 (USD Billion) by 2032. The Branded Generic Market CAGR (growth rate) is expected to be around 4.67% during the forecast period (2024 - 2032).

Source Primary Research, Secondary Research, MRFR Database and Analyst Review

Key Branded Generic Market Trends Highlighted

Branded generics, a hybrid of branded and generic pharmaceuticals, represent a significant trend in the pharmaceutical market. They combine the brand recognition and perceived quality of brand-name drugs with the lower costs associated with generics.

Key drivers behind the growth of this market include increasing healthcare costs, the expiration of patents on blockbuster drugs, and regulatory support for generic drug use.

Opportunities for branded generics lie in the potential to capture market share from both branded and generic drugs.

They offer a competitive advantage to manufacturers looking to differentiate their products in a crowded market. Recent trends in the branded generic market include the expansion into new therapeutic areas, such as oncology and biologics, and the adoption of direct-to-consumer advertising.

To succeed in this dynamic market, manufacturers should focus on developing high-quality products, building strong brand identities, and establishing partnerships with healthcare providers and distributors. By leveraging these trends and opportunities, the branded generic market is poised for continued growth in the coming years.

Branded Generic Market Drivers

Rising Prevalence of Chronic Diseases

The increasing prevalence of chronic diseases, such as diabetes, cardiovascular diseases, and cancer, is a major driver of the branded generic market. These diseases require long-term treatment, which often involves the use of multiple medications.

Branded generics offer a cost-effective alternative to branded drugs, making them an attractive option for patients and healthcare providers alike. The growing demand for affordable healthcare options is expected to continue to drive the growth of the branded generic market in the coming years.

Government Initiatives to Promote Generic Drug Use

Governments around the world are increasingly implementing policies to promote the use of generic drugs. These initiatives include measures such as mandatory generic substitution, price controls, and public awareness campaigns.

The aim of these policies is to reduce healthcare costs and improve access to essential medicines. The supportive regulatory environment is expected to create a favorable market landscape for branded generics, as they offer a cost-effective alternative to branded drugs while maintaining quality standards.

Technological Advancements in Drug Development and Manufacturing

Technological advancements are also playing a significant role in the growth of the branded generic market. The development of new technologies, such as biosimilars and 3D printing, is making it possible to produce high-quality generic drugs at a lower cost.

Additionally, the use of data analytics and artificial intelligence is helping to streamline the drug development and manufacturing process, further reducing costs and improving efficiency.

These technological advancements are expected to continue to drive the growth of the branded generic market in the coming years.

Branded Generic Market Segment Insights

Branded Generic Market Dosage Form Insights

The Branded Generic Market is segmented into various dosage forms, including Oral, Injectable, Transdermal, Topical, and Inhalable. Each dosage form has its unique characteristics, advantages, and target patient populations. Oral dosage forms are the most common and convenient, accounting for a significant share of the Branded Generic Market revenue.

They are easy to administer, have good bioavailability, and can be taken at home. Common examples of oral dosage forms include tablets, capsules, and liquids. Injectable dosage forms are used when rapid onset of action is required or when the drug cannot be taken orally.

They are typically administered by a healthcare professional and are used for conditions such as infections, pain management, and cancer treatment. The injectable segment is expected to grow at a steady pace, driven by the increasing prevalence of chronic diseases and the development of new injectable therapies.

Transdermal dosage forms are applied to the skin and allow the drug to be absorbed through the skin. They are often used for drugs that need to be delivered continuously over a period of time, such as pain relievers, hormones, and nicotine replacement therapy.

The transdermal segment is expected to witness significant growth due to the increasing adoption of non-invasive drug delivery methods. Topical dosage forms are applied directly to the skin or mucous membranes. They are commonly used for skin conditions such as eczema, psoriasis, and acne.

The topical segment is expected to grow steadily, driven by the rising prevalence of skin disorders and the development of new topical formulations. Inhalable dosage forms are used for the delivery of drugs to the lungs. They are commonly used for respiratory conditions, such as asthma, chronic obstructive pulmonary disease (COPD), and cystic fibrosis.

The inhalable segment is expected to grow at a moderate pace, driven by the increasing prevalence of respiratory diseases and the development of new inhalable therapies.

Overall, the Branded Generic Market segmentation by dosage form offers insights into the diverse needs of patients and the various delivery methods available for different drugs.

Each segment has its own growth drivers and challenges, and it is important for market participants to understand these dynamics to develop effective strategies.

Source Primary Research, Secondary Research, MRFR Database and Analyst Review

Branded Generic Market Therapeutic Area Insights

The Therapeutic Area segment is a crucial aspect of the Branded Generic Market, influencing market growth and industry dynamics. Cardiovascular, Oncology, Central Nervous System, Metabolic Disorders, and Anti-infective are key therapeutic areas with significant revenue contributions.

Cardiovascular dominates the market with a substantial share due to the prevalence of chronic heart conditions and increasing demand for branded generics. Oncology is another major segment, driven by the rising incidence of cancer and the development of innovative oncology therapies.

The Central Nervous System segment also holds a sizable market share, fueled by the growing burden of neurological disorders. Metabolic Disorders and Anti-infective segments are poised for steady growth due to increasing prevalence of diabetes and infectious diseases, respectively.

Understanding the therapeutic area segmentation provides insights into the market dynamics and helps stakeholders make informed decisions regarding product development, marketing strategies, and investment opportunities.

Branded Generic Market Generic Equivalent Insights

The Generic Equivalent segment of the Branded Generic Market is projected to grow significantly in the coming years, driven by increasing demand for affordable and accessible healthcare solutions. Biosimilar and non-biosimilar drugs are expected to contribute to this growth, with biosimilars gaining traction due to their lower cost and similar efficacy to their branded counterparts.

The Branded Generic Market revenue for Generic Equivalents is estimated to reach USD 28.4 billion in 2024, representing a CAGR of 5.2% from 2024 to 2032.

The non-biosimilar segment is expected to hold a larger market share, owing to the wider availability and lower cost of these drugs.

However, the biosimilar segment is projected to grow at a faster pace, driven by increasing acceptance and adoption by healthcare providers and patients.

Branded Generic Market Distribution Channel Insights

The distribution channel segment plays a crucial role in the Branded Generic Market. The market is segmented into four primary channels Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and Wholesale Distributors. Hospital Pharmacies accounted for the largest share of the market in 2023, and they are expected to maintain their dominance throughout the forecast period.

The growth in this segment can be attributed to factors such as the rising prevalence of chronic diseases, increasing healthcare expenditure, and the growing adoption of branded generics by hospitals.

Retail Pharmacies represent the second-largest segment, and they are expected to witness steady growth over the forecast period. The growth in this segment is driven by factors such as the increasing number of retail pharmacies, the convenience they offer, and the growing awareness of branded generics among consumers.

Online Pharmacies are gaining popularity, and they are expected to experience significant growth in the coming years. The growth in this segment can be attributed to factors such as the convenience they offer, the wide range of products they offer, and the competitive prices they offer.

Wholesale Distributors play a crucial role in the distribution of branded generics, and they are expected to witness steady growth over the forecast period.

The growth in this segment is driven by factors such as the increasing number of branded generics being introduced, the growing demand for branded generics from hospitals and retail pharmacies, and the increasing efficiency of the distribution network.

Branded Generic Market Product Insights

The Branded Generic Market is segmented into branded products and generic products. The generic products segment is expected to grow at a CAGR of 5.2% over the forecast period.

Branded products are typically more expensive than generic products, but they offer consumers a number of benefits, such as 1) higher quality, 2) better customer service, and 3) a more trusted brand name. Generic products are typically less expensive than branded products, but they may not offer the same level of quality or customer service.

The growth of the Branded Generic Market is being driven by a number of factors, including 1) the increasing popularity of online shopping, 2) the growing demand for affordable healthcare products, and 3) the rising awareness of the benefits of generic products.

Branded Generic Market Regional Insights

The regional segmentation of the Branded Generic Market presents distinct market dynamics and growth opportunities. North America is expected to remain the dominant regional market, accounting for a significant share of the Branded Generic Market revenue in 2023 and is projected to maintain its leadership position throughout the forecast period.

The region's well-established healthcare infrastructure, high adoption of branded generics, and increasing healthcare expenditure contribute to its dominance. Europe follows North America as the second-largest regional market, driven by robust demand from key countries such as Germany, France, and the United Kingdom.

The increasing prevalence of chronic diseases and government initiatives to promote branded generics are key growth factors in Europe. The Asia-Pacific (APAC) region is anticipated to witness substantial growth, with countries like China, India, and Japan emerging as prominent markets for branded generics.

The rising middle class, increasing healthcare awareness, and government support for healthcare reforms are driving the growth in this region. South America and the Middle East and Africa (MEA) regions are also expected to exhibit steady growth, with increasing healthcare expenditure and a growing population driving market expansion.

Source Primary Research, Secondary Research, MRFR Database and Analyst Review

Branded Generic Market Key Players and Competitive Insights

Major players in the Branded Generic Market industry are continuously striving to gain competitive advantage by adopting various strategies such as investing in new product development, expanding their product portfolio, and forming strategic alliances.

Leading Branded Generic Market players are focusing on increasing their market share by investing in research and development activities in order to develop innovative products that meet the evolving needs of consumers.

Branded Generic Market development is driven by the increasing demand for cost-effective and high-quality products, as well as the growing popularity of online shopping.

The Competitive Landscape of Branded Generic Market industry is expected to remain highly competitive in the coming years, as new entrants are expected to enter the market and existing players are expected to intensify their competitive strategies.

Teva Pharmaceutical Industries Ltd. is a leading player in the Branded Generic Market industry, with a strong focus on developing and manufacturing generic and branded generic pharmaceuticals. The company has a presence, with operations in over 80 countries.

Teva's Branded Generic Market products include a wide range of therapeutic areas, such as cardiovascular, respiratory, and central nervous system disorders. The company has a strong pipeline of new products, and it is expected to continue to expand its product portfolio in the coming years.

Pfizer Inc. is a major competitor in the Branded Generic Market industry, with a strong focus on developing and manufacturing branded generic and innovative pharmaceuticals. The company has a presence, with operations in over 150 countries.

Pfizer's Branded Generic Market products include a wide range of therapeutic areas, such as cardiovascular, respiratory, and oncology. The company has a strong pipeline of new products, and it is expected to continue to expand its product portfolio in the coming years.

Key Companies in the Branded Generic Market Include

• Mylan N.V.


• Teva Pharmaceutical Industries


• Mankind Pharma


• Intas Pharmaceuticals


• Sandoz AG


• Aurobindo Pharma


• Lupin


• Cipla


• Sun Pharmaceutical Industries


• Torrent Pharmaceuticals


• Reddy's Laboratories


• Alkem Laboratories


• Cadila Healthcare


• Apotex Inc.

Branded Generic Market Industry Developments

The market is driven by factors such as rising healthcare costs, increasing consumer awareness about generic drugs, and government initiatives to promote the use of generic medicines.

Key recent developments in the market include the launch of new branded generic drugs by pharmaceutical companies, strategic partnerships and acquisitions among market players, and the expansion of branded generic offerings in emerging markets.